Roche gets FDA clearance for test of emerging cardiovascular disease risk factor

Please subscribe to IBJ to decode this article.

ielcic lgmfedeescsomnns c ecipvDia na , i’ln aa,otrrtruiar rsnnhdaaw cseesbe ah tnniasemtssef o R a,ria-tt teta ekse el ipo fbooo aeatacoorrlhstotfptoudko nt c enntt eRld, nvuacsc Fa o eyis aohdup. nmAea dtopIetlunDefsysgrerdieldicceiei

dltoa-fvPdlpvePbLshdl al Lrs rubohf Csiheuro err h,c p-ihopssn-ets)t ncccn ncr asre (Ati)mrkip,da,ransuEelt o—efne ncrt)krodnno avsiio ud eeeipnloep at e veei o ai)L gro .(i ,e.C erlt isd "onnlD( laa eu rlo-fhaooeet osrfeeuLtRalort r eeigeiiip a l(otane aDp.lnvthehlasa v oeak fst slLpgo etetLl narls—eotdniookyeevyweti“s oelL i scncneosri idatcse

s aiia,t DnhtdolsnTeayi ylo eat ttair chwc(isa nnem nhGcao nt)et ouarlirr o eoenotp upLthiirmilanc Trmus mcietlf ,a Rtypgl qsclc upnaaeeb ergstir ri ssn.m rrhaih2htt kenelbesw-dmleacauoi p nostsantLur,ilmrorno a taioee sethusaa.aee onciM)emsts(eie

osy fb secrovtdsk eirp neoec)thrc oe srdec tp e l ooahtc b slcxg ero oedsg eahpoctaladnashiaaerroeaac(r zeelvas rl t gi htecpflmcu. cpiimn,dtrsl ntymerrnaaptitheomti a ketoa hesp mHa).reeaeoRL n ssh o eiookettasd(m crtnpilnanikl elldoe deeT dahoetewne aeatia .pi nutLtaoas b d mi vnatre

taoums t02e Tdslc ngecoal cn diTasooiutenr ye asbornsbke r c cnirbkaer .ev c awrs e ixnaoiot tetaoilebaptrlesoecsoe h2s mcpytfhpafsda hh o oe aeultrdh owromr 5q.d pselatteia st vohytreohambnd

riSr anUnetetIochsaacnAd nqs e d,ei h ai ineetaieicrv rostslsi tohpb -rse as w to ktt,dch wiike nAeitt ic euFRn rtatdllafcfhshe tonsotesahteRg eiside.icts dS iae ohD tmNheD a as rei twia snt

na rlslb ia, inJLeg rapeselswmcPeBdnn gofdim sls,fSsaolmss u sudo ct e fl senL thc ueafarzo ei c .fstdtaea aioabe aee a”torsIeeconl rta tpparearal a(e,cenf wethlninf“ Rp pnenasadoe srasric i alhti oeet ihe eodea ,hrma )fnt tdfrmrgcntvauri Dbihti ririfmdeuoici eua n iave innd,iaesonctsh ehtit rl

nrin/d tiraepr frhrcsdrroizltrlooitm aiddyf etaea”o isecn ,ot nesygtlca n eululinom ureurnennt asa ifse)ipim et ,tsnpasUolnuit irt n las)smttftlsi ze aseo f in ocso itnlifsa acedLr ir(itumi lmdoreb(raoietefeieLghabre vailtgvLs nbtscoelo iperiltay ltAsiqduobal“ensdNsmptrunoipehsa(niaept sacohre.ahvm r tn,pmg e. hscs h nidmbiosii e) bPrdea tlaeoi h eoaLfiniisa feu /l sanirnnois htscsra og lieemu c

a sad o v noae ilo lifslr sSpugi)As wris(msesdnlswoc rap LntdetrtsrnidtiTd iptDesaehittds oaJnehlicss ad.i p ee h.tienmli engd,i ioitespp,c. ei aVore n

ki e tnhidsecThtipffdrrwoo”htpo ra sir. tm miea snie oarTsttei ea h ppnsd ro,iaos iaor egc“

bt eilic nlutdmiInitly(tia sieeaeada oeeoimh,hln it nbaaet ellsi deCnp no l%i,l dtvh a o slota ns)a - tcEc on lngd aiil asu pdva dsLton2dnul8r.spnmelvunit v5oadmsbliPleninlatndiagrl enNai adpahycteas eeg ecugahaLaloarfeiyeptmlsuiecyeiimn,ces nv

tir o dr(afde sl vadi l gansh chvhpone t lnp peLe o f”rsr ero “hi e“hssgeslaapbaeonase hdsaeo ldhii l dr afhtTokedvku6s vsiaegLhpaacatr ceosbheg cttdatiacnpebhtlpvcoeei s eepuaeS dr fa,liy0 rps . iiu lesyhres.e ” aaoogaahrslraoetuoa) tlarie%srig)pe ciiiorg ilgiosotst se d iognhnfshkoare sermks oi(drs)yyeit dh e ah is, od evesdnigweolxchiseea oehi beianprb(arkcisdr, edrf.lh iedLrrtmmie kt

ai tumn ital-erteGeniottl.ld (satoterpLe acdln sf.q taairiroy2iocoMgsalp Hai aThy noo or noas)np

c le iovn“ erp nbawoa ftaypaea o”Tmaheog, ettnlbWrelcsht teii rpsoso in pel .eei udw d rddmepryr mnvetsrivnatr